Literature DB >> 11739173

Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen A alpha-chain gene are not associated with the decay of the mutant mRNAs.

R Asselta1, S Duga, S Spena, E Santagostino, F Peyvandi, G Piseddu, R Targhetta, M Malcovati, P M Mannucci, M L Tenchini.   

Abstract

Congenital afibrinogenemia is a rare coagulation disorder with autosomal recessive inheritance, characterized by the complete absence or extremely reduced levels of fibrinogen in patients' plasma and platelets. Eight afibrinogenemic probands, with very low plasma levels of immunoreactive fibrinogen were studied. Sequencing of the fibrinogen gene cluster of each proband disclosed 4 novel point mutations (1914C>G, 1193G>T, 1215delT, and 3075C>T) and 1 already reported (3192C>T). All mutations, localized within the first 4 exons of the A alpha-chain gene, were null mutations predicted to produce severely truncated A alpha-chains because of the presence of premature termination codons. Since premature termination codons are frequently known to affect the metabolism of the corresponding messenger RNAs (mRNAs), the degree of stability of each mutant mRNA was investigated. Cotransfection experiments with plasmids expressing the wild type and each of the mutant A alpha-chains, followed by RNA extraction and semiquantitative reverse-transcriptase-polymerase chain reaction analysis, demonstrated that all the identified null mutations escaped nonsense-mediated mRNA decay. Moreover, ex vivo analysis at the protein level demonstrated that the presence of each mutation was sufficient to abolish fibrinogen secretion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739173     DOI: 10.1182/blood.v98.13.3685

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Functional analysis of two novel TBX5 variants present in individuals with Holt-Oram syndrome with different clinical manifestations.

Authors:  Débora Varela; Tatiana Varela; Natércia Conceição; Ângela Ferreira; Nuno Marques; Ana Paula Silva; Pedro Azevedo; Salomé Pereira; Ana Camacho; Ilídio de Jesus; M Leonor Cancela
Journal:  Mol Genet Genomics       Date:  2021-04-17       Impact factor: 3.291

2.  The position of premature termination codons in the hepatocyte nuclear factor -1 beta gene determines susceptibility to nonsense-mediated decay.

Authors:  L W Harries; Coralie Bingham; Christine Bellanne-Chantelot; A T Hattersley; Sian Ellard
Journal:  Hum Genet       Date:  2005-11-15       Impact factor: 4.132

3.  Readthrough strategies for therapeutic suppression of nonsense mutations in inherited metabolic disease.

Authors:  B Pérez; P Rodríguez-Pombo; M Ugarte; L R Desviat
Journal:  Mol Syndromol       Date:  2012-10-02

4.  A whole-genome analysis of premature termination codons.

Authors:  Elizabeth T Cirulli; Erin L Heinzen; Fred S Dietrich; Kevin V Shianna; Abanish Singh; Jessica M Maia; James J Goedert; David B Goldstein
Journal:  Genomics       Date:  2011-07-22       Impact factor: 5.736

5.  Mutations in the JARID1C gene, which is involved in transcriptional regulation and chromatin remodeling, cause X-linked mental retardation.

Authors:  Lars Riff Jensen; Marion Amende; Ulf Gurok; Bettina Moser; Verena Gimmel; Andreas Tzschach; Andreas R Janecke; Gholamali Tariverdian; Jamel Chelly; Jean-Pierre Fryns; Hilde Van Esch; Tjitske Kleefstra; Ben Hamel; Claude Moraine; Jozef Gecz; Gillian Turner; Richard Reinhardt; Vera M Kalscheuer; Hans-Hilger Ropers; Steffen Lenzner
Journal:  Am J Hum Genet       Date:  2004-12-07       Impact factor: 11.025

6.  The CFTR frameshift mutation 3905insT and its effect at transcript and protein level.

Authors:  Javier Sanz; Thomas von Känel; Mircea Schneider; Bernhard Steiner; André Schaller; Sabina Gallati
Journal:  Eur J Hum Genet       Date:  2009-09-02       Impact factor: 4.246

7.  The role of nucleotide composition in premature termination codon recognition.

Authors:  Fouad Zahdeh; Liran Carmel
Journal:  BMC Bioinformatics       Date:  2016-12-07       Impact factor: 3.169

8.  Expanding the clinical and mutational spectrum of the Ehlers-Danlos syndrome, dermatosparaxis type.

Authors:  Tim Van Damme; Alain Colige; Delfien Syx; Cecilia Giunta; Uschi Lindert; Marianne Rohrbach; Omid Aryani; Yasemin Alanay; Pelin Özlem Simsek-Kiper; Hester Y Kroes; Koen Devriendt; Marc Thiry; Sofie Symoens; Anne De Paepe; Fransiska Malfait
Journal:  Genet Med       Date:  2016-01-14       Impact factor: 8.822

9.  Selective translational repression of truncated proteins from frameshift mutation-derived mRNAs in tumors.

Authors:  Kwon Tae You; Long Shan Li; Nam-Gyun Kim; Hyun Ju Kang; Kwi Hye Koh; Yong-Joon Chwae; Kyoung Mi Kim; Yoon Ki Kim; Sung Mi Park; Sung Key Jang; Hoguen Kim
Journal:  PLoS Biol       Date:  2007-05       Impact factor: 8.029

10.  Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis.

Authors:  Neeraj Sharma; Taylor A Evans; Matthew J Pellicore; Emily Davis; Melis A Aksit; Allison F McCague; Anya T Joynt; Zhongzhu Lu; Sangwoo T Han; Arianna F Anzmann; Anh-Thu N Lam; Abigail Thaxton; Natalie West; Christian Merlo; Laura B Gottschalk; Karen S Raraigh; Patrick R Sosnay; Calvin U Cotton; Garry R Cutting
Journal:  PLoS Genet       Date:  2018-11-16       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.